Leung Alex K K, Tam Yuen Yi C, Cullis Pieter R
Department of Biochemistry and Molecular Biology, The University of British Columbia, Vancouver, BC, Canada.
Adv Genet. 2014;88:71-110. doi: 10.1016/B978-0-12-800148-6.00004-3.
The discovery of RNA interference (RNAi) in mammalian cells has created a new class of therapeutics based on the reversible silencing of specific disease-causing genes. This therapeutic potential depends on the ability to deliver inducers of RNAi, such as short-interfering RNA (siRNA) and micro-RNA (miRNA), to cells of target tissues. This chapter reviews various challenges and delivery strategies for siRNA, with a particular focus on the development of lipid nanoparticle (LNP) delivery technologies. Currently, LNP delivery systems are the most advanced technology for systemic delivery of siRNA, with numerous formulations under various stages of clinical trials. We also discuss methods to improve gene silencing potency of LNP-siRNA, as well as application of LNP technologies beyond siRNA to the encapsulation of other nucleic acids such as mRNA and clustered regularly interspaced short palindromic repeats (CRISPR).
RNA干扰(RNAi)在哺乳动物细胞中的发现催生了一类基于可逆沉默特定致病基因的新型疗法。这种治疗潜力取决于将RNAi诱导剂(如小干扰RNA(siRNA)和微小RNA(miRNA))递送至靶组织细胞的能力。本章综述了siRNA面临的各种挑战和递送策略,特别关注脂质纳米颗粒(LNP)递送技术的发展。目前,LNP递送系统是用于siRNA全身递送的最先进技术,有多种制剂正处于临床试验的不同阶段。我们还讨论了提高LNP-siRNA基因沉默效力的方法,以及LNP技术在siRNA之外用于封装其他核酸(如mRNA和成簇规律间隔短回文重复序列(CRISPR))的应用。